Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc (ticker: RARE) is a clinical‑stage and commercial biotechnology company focused on developing therapies for rare and ultra‑rare genetic diseases. With a market capitalisation of about $3.29bn, the firm combines marketed products with an active pipeline of biologics and gene‑therapy candidates. Key value drivers for the stock typically include clinical trial readouts, regulatory decisions, commercial uptake of approved products and partnering activity. Like many small‑to‑mid cap biotech companies, Ultragenyx can be exposed to high research and development costs, binary clinical outcomes and market volatility. Investors should be aware that values can fall as well as rise and that past performance is not a guide to the future. This summary is for general, educational purposes only and is not personalised financial advice; investors should perform their own research or consult a regulated adviser to assess suitability for their individual circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ultragenyx stock, expecting it to rise significantly in value.
Financial Health
Ultragenyx Pharmaceutical Inc. is producing strong revenue and cash flow with a solid profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RARE
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketOrphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can create significant movement; these events are opportunities to learn about risk‑reward, though outcomes can be binary and unpredictable.
Commercial Traction Matters
Revenue growth from approved therapies and uptake by specialists can de‑risk the story; however, commercial execution and pricing pressures remain potential headwinds.
Partnering & Access
Collaborations and international expansion can extend reach and share costs, but dependency on partners and regulatory variance across markets add complexity and risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
